![]() |
市场调查报告书
商品编码
1797974
2032 年宠物肠道微生物组检测市场预测:按产品类型、宠物类型、样本类型、应用、最终用户和地区进行的全球分析Pet Gut Microbiome Testing Market Forecasts to 2032 - Global Analysis By Product Type, Pet Type, Sample Type, Application, End User and By Geography |
根据 Stratistics MRC 的数据,全球宠物肠道微生物组检测市场预计在 2025 年达到 6,106 万美元,预计到 2032 年将达到 1.736 亿美元,预测期内的复合年增长率为 16.1%。
宠物肠道微生物组检测是一种诊断过程,利用粪便样本分析宠物消化道的微生物组成。此检测可识别有益菌和有害菌,从而深入了解宠物的消化系统健康、免疫功能和潜在的饮食敏感性。透过评估微生物多样性和平衡性,兽医和饲主可以客製化营养和治疗方案,以改善宠物的整体健康状况。此检测支持主动健康管理,及早发现肠道失衡和疾病征兆,并促进宠物肠道功能达到最佳状态。
据美国兽医内科学院称,研究人员分析了超过4000份宠物粪便样本,以确定健康微生物组的核心。他们发现,大约28%的狗和13%的猫体内常见的大肠桿菌-志贺氏菌(包括大肠桿菌)含量升高,并且这些升高的水平与临床症状、胃肠道诊断和近期抗生素暴露显着相关。
提高宠物的健康意识和人性化
随着宠物越来越被视为家庭成员,饲主也开始投资预防保健和个人化营养。这种转变推动了微生物组分析在检测消化器官系统问题、过敏和免疫相关疾病的应用。宠物肠道微生物组检测恰好满足了这一需求,它提供了一种识别潜在健康问题(例如胃肠道问题和过敏)的方法,并在问题发展成慢性或严重疾病之前製定有针对性的干预措施。整体兽医护理和以健康为中心的宠物产品的兴起,进一步推动了这个市场的扩张。
测试成本高且解释复杂
虽然技术进步使得检测更加经济实惠,但它仍然是加值服务,并非所有饲主都能享受,尤其是饲主注重价格的宠物主人。此外,这些检测产生的数据的复杂性也带来了挑战。结果通常包含大量的微生物种类及其相对丰度列表,这对于宠物饲主,甚至一些兽医来说,都难以解读并转化为切实可行的建议。
直接面向消费者 (DTC) 模式和数位集成
DTC检测套组可让宠物饲主在家采集样本,简化流程并提升便利性。这种模式避免了去看兽医的需要,提高了可及性和消费者参与度。透过将此类家用试剂套件与数位平台结合,公司可以为宠物饲主提供易于理解的报告、个人化的饮食建议以及联繫营养专家的管道。这些技术的无缝整合不仅提升了用户体验,还创建了一个扩充性的经营模式,以覆盖更广泛的客户群。
来自科学界和兽医界的怀疑
由于担心微生物组数据的临床有效性、缺乏同行评审检验以及结果不一致,人们对此持谨慎态度。一些专家质疑缺乏坚实科学依据的微生物学介入措施的有效性。除非有严谨的研究和标准化方案的支持,否则这种怀疑态度可能会阻碍其融入主流兽医学。由于缺乏对标准化方法和结果解释的强有力的科学共识,检测公司可能难以在一个高度依赖专家建议的市场中获得信誉并推动其广泛应用。
新冠疫情对宠物肠道微生物组检测市场产生了重大且正面的影响。在疫情封锁期间,宠物拥有量大幅成长,这让人们更加重视人与动物之间的纽带,并推动了宠物健康和保健支出的成长。随着饲主居家时间增加,对宠物健康的关注度也随之增加,这种「宠物人性化」趋势也随之加速。疫情也凸显了居家健康监测和诊断的价值,直接推动了对便捷的直销型检测套组的需求。
DNA定序套件市场预计将成为预测期内最大的市场
由于DNA定序套件盒技术提供卓越的准确性和全面的数据,预计在预测期内将占据最大的市场占有率。采用16S rRNA定序和散弹枪宏基因体学等技术的套件被认为是肠道微生物组分析的黄金标准,能够深入了解宠物肠道中的细菌组成、多样性和功能。这些先进的试剂套件对于诊断和研究都至关重要,因为它们能够提供製定个人化治疗方案和开发新型宠物保健产品所需的深入资讯。
预计诊断领域在预测期内将以最高的复合年增长率成长。
预计诊断领域将在预测期内实现最高成长率,这得益于对可操作健康洞察日益增长的需求。基于微生物组的诊断方法正被用于检测宠物的胃肠道疾病、食物敏感性和免疫失衡。随着人们日益意识到肠道健康对整体健康的影响,诊断工具也不断发展,以提案针对性的治疗方法。与人工智慧主导平台和个人化护理计画的整合,正在强化微生物组诊断的价值提案。
预计亚太地区将在预测期内占据最大的市场占有率,这得益于宠物拥有量的增长、可支配收入的提高以及兽医基础设施的不断扩张。中国、日本和印度等国家在宠物保健和健康产品上的支出正在增加。该地区人口技术娴熟,数位健康解决方案的快速普及,正在推动微生物组检测服务的需求。本地新兴企业和全球企业正在投资客製化服务,以满足多样化的消费者需求。
由于都市化加快和宠物照护趋势的演变,预计亚太地区将在预测期内实现最高的复合年增长率。该地区对预防性卫生和营养的认识日益提高,推动了先进诊断方法的采用。政府对生物技术创新的支持以及定序技术的日益普及,进一步促进了市场的成长。随着宠物饲主寻求个人化和全面的护理,亚太地区已成为微生物组检测创新和扩展的关键枢纽。
According to Stratistics MRC, the Global Pet Gut Microbiome Testing Market is accounted for $61.06 million in 2025 and is expected to reach $173.6 million by 2032 growing at a CAGR of 16.1% during the forecast period. Pet gut microbiome testing is a diagnostic process that analyzes the microbial composition within a pet's gastrointestinal tract using stool samples. This test identifies beneficial and harmful bacteria, offering insights into digestive health, immune function, and potential dietary sensitivities. By evaluating microbial diversity and balance, veterinarians and pet owners can tailor nutrition and treatment plans to improve overall wellness. It supports proactive health management, helping detect early signs of imbalance or disease and promoting optimal gut function in pets.
According to American College of Veterinary Internal Medicine, researchers analyzed over 4,000 fecal samples from pets to define a core healthy microbiome. They found that elevated levels of Escherichia-Shigella commonly including E. coli were present in approximately 28% of dogs and 13% of cats, and these elevations were significantly associated with clinical signs, gastrointestinal diagnoses, and recent antibiotic exposure
Growing pet health awareness & humanization of pets
As pets are increasingly viewed as family members, owners are investing in preventive care and personalized nutrition. This shift is encouraging the adoption of microbiome analysis to detect digestive issues, allergies, and immune-related conditions. Pet gut microbiome testing fits this need perfectly, as it offers a way to identify underlying health issues, such as gastrointestinal problems and allergies, and to develop targeted interventions before they become chronic and severe. The rise of holistic veterinary care and wellness-focused pet products further supports the expansion of this market.
High costs of testing & complexity of interpretation
While technological advancements have made the process more affordable, it remains a premium service that is not accessible to all pet owners, particularly those who are more price-sensitive. Furthermore, the complex nature of the data generated by these tests poses a challenge. The results, often including extensive lists of microbial species and their relative abundances, can be difficult for both pet owners and even some veterinarians to interpret and translate into actionable advice.
Direct-to-consumer (DTC) models & digital integration
DTC testing kits, which allow pet owners to collect samples at home, simplify the process and make it more convenient. This model bypasses the need for a veterinary visit, increasing accessibility and consumer engagement. By combining these at-home kits with digital platforms, companies can provide pet owners with easy-to-understand reports, personalized dietary recommendations, and access to nutritional experts. This seamless integration of technology not only enhances the user experience but also creates a scalable business model for reaching a broader customer base.
Skepticism from the scientific and veterinary communities
Concerns about the clinical relevance of microbiome data, lack of peer-reviewed validation, and inconsistent outcomes have led to cautious adoption. Some professionals question the efficacy of microbiome-based interventions without robust scientific backing. This skepticism may hinder integration into mainstream veterinary care unless supported by rigorous studies and standardized protocols. The absence of a strong scientific consensus on standardized methods and the interpretation of results can make it difficult for testing companies to gain credibility and drive widespread adoption in a market that relies heavily on professional advice.
The COVID-19 pandemic had a profound and generally positive impact on the pet gut microbiome testing market. During lockdowns, there was a significant surge in pet ownership and a new emphasis on the human-animal bond, leading to increased spending on pet health and wellness. This "pet humanization" trend accelerated as owners spent more time at home and became more attentive to their pets' well-being. The pandemic also highlighted the value of at-home health monitoring and diagnostics, which directly boosted the demand for convenient, direct-to-consumer testing kits.
The DNA sequencing kits segment is expected to be the largest during the forecast period
The DNA sequencing kits segment is expected to account for the largest market share during the forecast period attributed to the superior accuracy and comprehensive data provided by these technologies. Kits utilizing methods like 16S rRNA sequencing and shotgun metagenomics are considered the gold standard for gut microbiome analysis, offering detailed insights into the bacterial composition, diversity, and function within a pet's gut. These advanced kits are critical for both diagnostic purposes and for research, as they provide the depth of information needed for personalized treatment plans and for the development of new, targeted pet health products.
The diagnostics segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the diagnostics segment is predicted to witness the highest growth rate driven by increasing demand for actionable health insights. Microbiome-based diagnostics are being used to detect gastrointestinal disorders, food sensitivities, and immune imbalances in pets. As awareness of gut health's impact on overall wellness grows, diagnostic tools are evolving to offer targeted treatment recommendations. Integration with AI-driven platforms and personalized care plans is enhancing the value proposition of microbiome diagnostics.
During the forecast period, the Asia Pacific region is expected to hold the largest market share supported by rising pet ownership, growing disposable income, and expanding veterinary infrastructure. Countries like China, Japan, and India are witnessing increased spending on pet healthcare and wellness products. The region's tech-savvy population and rapid adoption of digital health solutions are fueling demand for microbiome testing services. Local startups and global players are investing in tailored offerings to meet diverse consumer needs.
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR owing to accelerating urbanization and evolving pet care trends. The region's growing awareness of preventive health and nutrition is encouraging adoption of advanced diagnostics. Government support for biotech innovation and increasing availability of sequencing technologies are further contributing to market growth. As pet owners seek personalized and holistic care, Asia Pacific is emerging as a key hub for microbiome testing innovation and expansion.
Key players in the market
Some of the key players in Pet Gut Microbiome Testing Market include AnimalBiome, Biome9, Sun Genomics, Nom Nom, Zesty Paws, PetBiome, Microbiome Labs, Basepaws, Pooch & Mutt, Wild Earth, Fera Pet Organics, DoggyBiome, MySimplePetLab, Vetrinex Labs, Four Leaf Rover and Bernie's Perfect Poop.
In May 2025, AnimalBiome reviewed over 12,500 patients tested and support extended to 4,500+ veterinary hospitals. The update also highlighted new strategic partnerships and the launch of the AnimalBiome Veterinary Academy.
In May 2025, Sun Genomics continued expansion in microbiome research initiatives. oted for ongoing research into microbiome-targeted interventions across diverse health conditions including gastrointestinal and metabolic disorders.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.